Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
详细信息 查看全文
- 作者：Qiaoqiao Li (1) (2)
Yonghong Hu (1) (2)
Mian Xi (1) (2)
Liru He (1) (2)
Lei Zhao (1) (2)
Mengzhong Liu (1) (2) - 关键词：Hepatocellular carcinoma ; Radiation ; Sorafenib ; Apoptosis ; DNA damage repair
- 刊名：BMC Cancer
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：623KB
- 参考文献：1. Parkin DM: Global cancer statistics in the year 2000. / Lancet Oncol 2001,2(9):533-43. CrossRef
2. Hung H: Treatment modalities for hepatocellular carcinoma. / Curr Cancer Drug Targets 2005,5(2):131-38. CrossRef
3. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. / J Clin Oncol 2005,23(34):8739-747. CrossRef
4. Seong J, Lee IJ, Shim SJ, Lim Do H, Kim TH, Kim JH, Jang HS, Kim MS, Chie EK, Nam TK, / et al.: A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. / Liver Int 2009,29(2):147-52. CrossRef
5. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, / et al.: Local radiotherapy for patients with unresectable hepatocellular carcinoma. / Int J Radiat Oncol Biol Phys 2005,61(4):1143-150. CrossRef
6. Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. / Drugs Today (Barc) 2005,41(12):773-84. CrossRef
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, / et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. / Lancet Oncol 2009,10(1):25-4. CrossRef
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, / et al.: Sorafenib in advanced hepatocellular carcinoma. / N Engl J Med 2008,359(4):378-90. CrossRef
9. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. / Cancer Res 2006,66(24):11851-1858. CrossRef
10. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, / et al.: Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. / Cancer Res 2007,67(19):9443-454. CrossRef
11. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM, Wilson GD: Sorafenib and radiation: a promising combination in colorectal cancer. / Int J Radiat Oncol Biol Phys 2010,78(1):213-20. CrossRef
12. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ: Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. / Clin Genitourin Cancer 2007,5(4):291-94. CrossRef
13. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, Tai HC, Wang CH, Shueng PW, Chen YJ: Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. / Clin Drug Investig 2009,29(1):65-1. CrossRef
14. Zhang Y, Chen LH, Wang L, Wang HM, Zhang YW, Shi YS: Radiation-inducible PTEN expression radiosensitises hepatocellular carcinoma cells. / Int J Radiat Biol 2010,86(11):964-74. CrossRef
15. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei D, Kang T, Zeng YX: Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. / J Biol Chem 2010,285(7):4931-940. CrossRef
16. Cao JX, Cui YX, Long ZJ, Dai ZM, Lin JY, Liang Y, Zheng FM, Zeng YX, Liu Q: Pluripotency-associated genes in human nasopharyngeal carcinoma CNE-2 cells are reactivated by a unique epigenetic sub-microenvironment. / BMC Cancer 2010, 10:68. CrossRef
17. Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF: ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. / Mol Cancer Ther 2009,8(4):873-82. CrossRef
18. Eriksson D, Stigbrand T: Radiation-induced cell death mechanisms. / Tumour Biol 2010,31(4):363-72. CrossRef
19. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14--3Sigma is required to prevent mitotic catastrophe after DNA damage. / Nature 1999,401(6753):616-20. CrossRef
20. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G: Cell death by mitotic catastrophe: a molecular definition. / Oncogene 2004,23(16):2825-837. CrossRef
21. Lukas J, Lukas C, Bartek J: Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. / DNA Repair (Amst) 2004,3(8-):997-007. CrossRef
22. Cann KL, Hicks GG: Regulation of the cellular DNA double-strand break response. / Biochem Cell Biol 2007,85(6):663-74. CrossRef
23. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/485/prepub - 作者单位：Qiaoqiao Li (1) (2)
Yonghong Hu (1) (2)
Mian Xi (1) (2)
Liru He (1) (2)
Lei Zhao (1) (2)
Mengzhong Liu (1) (2)
1. Department of Radiation Oncology, SunYat-sen University Cancer Center Guangzhou, 651 Dongfeng Road East, Guangzhou, 510060, China
2. State Key Laboratory of Oncology in South China, Guangzhou, China - ISSN：1471-2407
文摘
Background Hepatocellular carcinoma (HCC) has a high incidence and mortality. Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether sorafenib modulated the response of HCC cells to irradiation in vitro, effect of timing of sorafenib, and the underlying mechanisms. Methods Cell viability of the HCC cell lines, SMMC-7721 and Bel-7402, was examined by the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2?H-terazolium (MTT) assays. Clonogenic growth assays of SMMC-7721 and Bel-7402 were determined by colony formation assays. DNA damage was assessed by monitoring γ-HAX foci in irradiated cells with immunofluorescence microscopy, and cell cycle distribution changes were examined by flow cytometry. Effects of sorafenib (15?μM) added 30?min prior to radiation (pre-irradiation sorafenib) of SMMC-7721 and BEL-7402 or 24?h post-irradiation (post-irradiation sorafenib) on irradiated SMMC-7721 and BEL-7402 cells were compared to those of radiation alone or no treatment. Results The effect of sorafenib was dependent on its time of addition in relationship to irradiation of cells. Pre-irradiation sorafenib did not significantly affect the viability of SMMC-7221 and BEL-7402 cells compared with irradiation treatment alone. In contrast, post-irradiation sorafenib increased the sensitivity of irradiated SMMC-7221 and BEL-7402 cells significantly in a time-dependent manner. Pre-irradiation sorafenib significantly increased the surviving fraction of SMMC-7221 and BEL-7402 cells in clonogenic assays whereas post-irradiation sorafenib significantly reduced the surviving fractions of SMMC-7221 and BEL-7402 cells. SMMC-7721 cells treated with sorafenib 30?min before irradiation had significantly fewer cells with γ-H2AX foci (23.8?±-.9%) than SMMC-7721 cells receiving radiation alone (59.9?±-.4; P-lt;-.001). Similarly, BEL-7402 cells receiving sorafenib prior to irradiation had significantly fewer cells with γ-H2AX foci (46.4?±-.8%) than those receiving radiation alone (25.0?±-.0%; P-lt;-.001). In addition, irradiation (6?Gy) caused a significant increase in the percentage of both SMMC-7721 and BEL-7402 cells in G2/M at 12 to 16?h post irradiation, which was markedly delayed by pre-irradiation sorafenib. Conclusions Sorafenib combined with irradiation exerted a schedule-dependent effect in HCC cells in vitro, which has significant implications for the combined use of sorafenib and radiotherapy for HCC patients.